Literature DB >> 12561009

Therapeutic biliary endoscopy.

E L Fogel1, S Sherman, S-H Park, L McHenry, G A Lehman.   

Abstract

Some steps of progress have been seen in the area of biliary therapeutic endoscopy, in the understanding and management of primary sclerosing cholangitis, problems relating to liver transplantation, malignant biliary strictures, complications after endoscopic retrograde cholangiopancreatography, sphincter of Oddi dysfunction, and tissue sampling. The benefits (or lack thereof) of preoperative biliary drainage in the setting of malignant obstructive jaundice have received an extensive review.

Entities:  

Mesh:

Year:  2003        PMID: 12561009     DOI: 10.1055/s-2003-37011

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  4 in total

Review 1.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

2.  N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis.

Authors:  Janusz Milewski; Grazyna Rydzewska; Malgorzata Degowska; Maciej Kierzkiewicz; Andrzej Rydzewski
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

3.  Effect of ERCP utilization and biliary complications on post-liver-transplantation mortality and graft survival.

Authors:  A Sidney Barritt; C Brock Miller; Paul H Hayashi; Evan S Dellon
Journal:  Dig Dis Sci       Date:  2010-04-22       Impact factor: 3.199

4.  Differential Diagnosis of Immunoglobulin G4-associated Cholangitis From Cholangiocarcinoma.

Authors:  Shunda Du; Gang Liu; Xinqi Cheng; Yue Li; Qian Wang; Ji Li; Xin Lu; Yongchang Zheng; Haifeng Xu; Tianyi Chi; Haitao Zhao; Yiyao Xu; Xinting Sang; Shouxian Zhong; Yilei Mao
Journal:  J Clin Gastroenterol       Date:  2016-07       Impact factor: 3.062

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.